Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Inclusion Criteria: * Written informed consent in accordance with federal, local, and institutional guidelines * Patients with metastatic pancreatic adenocarcinoma not treated with chemotherapy for metastatic disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Bilirubin \< 2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 times ULN) * Alanine aminotransferase (ALT) \< 2.5 times ULN * Serum creatinine =\< 1.5 mg/dL * Serum albumin \>= 3.0 g/dL * Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose * Patients with history of previously treated malignancies who have no evidence of disease for last five years are allowed to participate Exclusion Criteria: * Patients who …